Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + tazemetostat in selected advanced solid tumors
2019-003303-35Phase 2Active
- Sponsor
- Institut Bergonié
- Start
- Jan 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of durvalumab and tazemetostat in pancreatic cancer (PC), colorectal cancer (CRC), Nonhematologic neoplasms and 1 more (4 cohorts), sponsored by Institut Bergonié. Primary endpoint: Disease control rate within 24 weeks. Started Jan 2021; status: active.
02
Drugs
durvalumabtazemetostat
03
Conditions
pancreatic cancer (PC)colorectal cancer (CRC)Nonhematologic neoplasmssoft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2019-003303-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003303-35.